logo
[김대균의 영어산책] 속담과 명언

[김대균의 영어산책] 속담과 명언

Korea Herald18-04-2025
필자는 최근 일본의 유명 출판사와 새로운 토익수출계약을 맺었다, 대만수출도 꾸준히 하고 있다. 필자의 칼럼에 일본독자나 선생님들이 자주 등장하는 것은 이런 맥락도 있다. 서로 교류하면서 배우기 때문이다. 일본은 우리나라보다 토익평균점수가 150점 낮기 때문에 한국 교재를 그대로 출간해서는 반응이 거의 없다. 일본 독자의 눈높이에 맞춰야 한다. 책의 내용도 우리나라 분량의 50%정도가 적당하다. 개인사업을 하면서 배운 점 중에 내가 잘하는 것과 좋아하는 것을 하는 것도 중요하지만 소비자의 필요를 맞추지 않으면 살아남지 못하는 시대가 되었다. 그만큼 살기 힘들지만 보람이 있는 것이 토익시장이다. 오늘은 건강과 부자에 관한 영어명언으로 영어 공부를 해보자! 아래 제공되는 명언 중에 몇가지를 암기해 보자! 독자들은 더욱 더 건강한 부자가 될 것이다.
건강 관련 속담과 명언 (Health)
1. "It is health that is real wealth and not pieces of gold and silver."
진정한 부는 금이나 은이 아니라 건강이다.
– Mahatma Gandhi
2. "A healthy outside starts from the inside."
건강한 겉모습은 내면에서 시작된다.
– Robert Urich
3. "Take care of your body. It's the only place you have to live."
당신의 몸을 돌보세요. 거기가 당신이 살 수 있는 유일한 곳입니다.
– Jim Rohn
4. "An ounce of prevention is worth a pound of cure."
한 온스의 예방이 일 파운드의 치료보다 낫다.
– Benjamin Franklin
5. "He who has health has hope, and he who has hope has everything."
건강한 사람은 희망이 있고, 희망이 있는 사람은 모든 것을 가진 것이다.
– Arabian Proverb
6."Happiness lies, first of all, in health."
행복은 무엇보다 건강에 있다.
– George William Curtis
7. "Your body hears everything your mind says."
당신의 몸은 당신의 마음이 말하는 모든 것을 듣고 있다.
– Naomi Judd
8. "He who takes medicine and neglects diet wastes the skill of his doctors."
약을 먹으면서 식단을 무시하는 사람은 의사의 기술을 낭비하는 것이다.
– Chinese Proverb (중국 속담)
9. "Those who think they have no time for healthy eating will sooner or later have to find time for illness."
건강한 식사를 할 시간이 없다고 생각하는 사람은 머지않아 병을 위한 시간을 내야 할 것이다.
– Edward Stanley
10. "Laughter is the best medicine."
웃음은 최고의 약이다.
– 영어 속담 (Proverb)
부와 돈에 관한 속담과 명언 (Wealth / Money)
1. "The lack of money is the root of all evil."
돈이 없는 것이 모든 악의 근원이다.
– Mark Twain
2. "Too many people spend money they haven't earned, to buy things they don't want, to impress people they don't like."
너무 많은 사람들이 벌지도 않은 돈으로, 원하지도 않는 물건을, 좋아하지도 않는 사람들을 감동시키기 위해 쓴다.
– Will Rogers
3. "Wealth consists not in having great possessions, but in having few wants."
부유함이란 많은 소유에 있는 것이 아니라, 적은 욕망에 있다.
– Epictetus
4. "Formal education will make you a living; self-education will make you a fortune."
정규 교육은 생계를 유지하게 해주고, 자기 주도 학습은 부를 안겨준다.
– Jim Rohn
5. "It's good to have money and the things that money can buy, but it's good too, to check up once in a while and make sure that you haven't lost the things that money can't buy."
돈과 돈으로 살 수 있는 것들을 가지는 것은 좋지만, 때때로 돈으로 살 수 없는 것을 잃지 않았는지도 확인하는 것이 좋다.
– George Lorimer
6. "A wise person should have money in their head, but not in their heart."
현명한 사람은 돈을 머릿속에만 두고, 마음속에는 두지 않는다.
– Jonathan Swift
7. "When health is absent, wealth is useless."
건강이 없으면, 부는 무용지물이다.
– Herophilus (고대 그리스 의사)
8. "Not everything that can be counted counts, and not everything that counts can be counted."
셀 수 있는 모든 것이 다 중요한 것은 아니며, 중요한 모든 것을 셀 수 있는 것도 아니다.
– Albert Einstein (의미 있는 부의 개념으로 자주 인용)
9. "If you want to feel rich, just count all the gifts you have that money can't buy."
부자가 된 기분을 느끼고 싶다면, 돈으로 살 수 없는 당신의 모든 소중한 것을 세어보라.
– 익명 (Anonymous)
10. "We make a living by what we get, but we make a life by what we give."
우리는 얻는 것으로 생계를 유지하지만, 주는 것으로 인생을 만들어간다.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Breaking Through Core CT Technology Barriers!
Breaking Through Core CT Technology Barriers!

Korea Herald

time04-08-2025

  • Korea Herald

Breaking Through Core CT Technology Barriers!

World-Class Innovations to Debut at 2025 Medtec in September SHANGHAI, Aug. 4, 2025 /PRNewswire/ -- A quiet revolution is underway in the field of high-end medical equipment, led by China's growing innovation power. Core CT technologies, once dominated by international giants, are now being steadily unlocked by Chinese companies, breaking through long-standing technical barriers. As a key showcase of this industrial transformation, the 2025 Medtec International Medical Device Design & Manufacturing Technology Exhibition will take place from September 24 to 26 at Halls 1 & 2, Shanghai World Expo Exhibition and Convention Center. The exhibition will reach a record-breaking scale of 45,000 square meters, bringing together over 1,000 top-tier companies from nearly 27 countries and regions around the world. Among the standout participants, Shanghai Xixin Medical Technology Co., Ltd., Guangzhou Wiserscope Photoelectric Medical Technology Co., Ltd., Wuxi Innosonics Medical Technology Co., Ltd., SmartVein (Jiaxing) Medical Technology Co., Ltd., and Shanghai AIMIC Medical Electronics Co., Ltd. will make major appearances, showcasing their latest technological breakthroughs and product applications to a highly targeted audience of professional buyers. Click to Register for FREE > 01. CT X-Ray Tubes: From Industry Bottleneck to the Rise of "Domestic Cores" In the realm of high-end medical devices, CT scanners are often referred to as the "eyes of modern medicine"—their performance directly impacts image quality and equipment lifespan. At the heart of these systems, the X-ray tube and detector act as the "retina" and "lens." For years, these critical components have been dominated by global giants like GE, Siemens, and Philips. As a result, Chinese medical institutions have faced costly challenges—millions spent on consumables and equipment outages lasting over a month while waiting for repairs. Now, change is underway. In the first half of 2025, the number of registered domestic CT devices surged by 47% year-over-year. Even more significant, the localization rate of core components has crossed the 60% threshold—a historic milestone. Behind this achievement lies the power of collaborative innovation, driven by coordinated efforts among upstream and downstream enterprises across the industry chain: 02. Localization Accelerates for the "Core" of CT Systems Driven by the rapid growth of China's healthcare industry and an aging population, domestic demand for CT systems and X-ray tubes continues to surge. Today, China has become the world's largest consumer market for medical CT tubes. According to recent medical procurement data, domestic CT system sales in 2024 have caught up with those of imported brands, with Chinese manufacturers now leading the market in share. Often referred to as the "core" of the CT system, the X-ray tube is a vital component in the medical imaging supply chain—accounting for roughly 20% of a CT system's bill of materials (BOM). As a high-value consumable, CT tubes typically need replacement every two and a half years. In high-volume hospitals, that replacement cycle can shorten to just one year. From 2022 to 2024, domestic demand for medical CT tubes was 12,275, 12,317, and 12,713 units, respectively—marking a 3.57% increase in 2024 compared to 2022. As a critical high-value consumable in medical CT equipment, a single CT tube can cost up to several million yuan. Data shows that the average lifespan of a CT tube in China is just 13 months—effectively requiring replacement nearly every year. The real challenge in CT tube manufacturing lies in achieving exceptional precision and stability. Given their high cost and short service life, CT tubes have become a competitive focal point between CT system manufacturers and tube suppliers. Domestic companies such as Kunshan Medical Source, CETC, Beijing SmartBeam, and Zhuhai Rcan have secured registrations for multiple CT tube models. For local CT system manufacturers, adopting domestically produced tubes offers a key technological advantage in reducing costs and boosting overall market competitiveness. Since the 12th Five-Year Plan, China has consistently identified CT tubes as a strategic focus for innovation and development. They have remained a priority across three consecutive national Five-Year Plans, underscoring strong government support for advancing homegrown CT tube manufacturing. At the same time, centralized procurement of medical devices is expanding across the country, with the trend gaining momentum. While global giants like GE Healthcare, Siemens Healthcare, and Philips still dominate the mid- to high-end market, they are increasingly facing pressure from rising domestic competitors. Backed by supportive policies and the growing strength of local technologies, the market share of domestically produced CT core components is expected to see steady and sustained growth. 03. 2025 Medtec: Discover Trends, Connect Resources, Unlock Opportunities Breakthroughs in independent innovation are not only transforming the domestic landscape but also offering fresh perspectives and solutions to the global medical technology community. The rapid advancement of localized CT core components marks a major milestone in the evolution of China's medical device industry. 2025 Medtec – the International Exhibition for Medical Device Design & Manufacturing Technology – will serve as a dynamic platform for technical exchange and business collaboration, further accelerating the localization and commercialization of CT core technologies. From domestically developed medical chips to automated precision components, and from non-invasive brain-computer interfaces to nanoscale surgical robots, 2025 Medtec will showcase a full spectrum of cutting-edge medical technologies from around the world. The event offers professionals a unique opportunity to engage in in-depth technical exchanges and gain insights that span from theoretical innovation to real-world industrial applications. Additionally, 2025 Medtec will host an enhanced Medtec International Medical Device Supply Chain Ecosystem Summit, centered on eight key themes: high-end active medical devices, manufacturing processes, innovative material applications, R&D consulting, medical regulations, consumer healthcare, market and procurement, and support services. This summit will foster collaboration and innovation throughout the supply chain. Attendees will have the chance to hear the latest industry insights, engage in direct discussions with experts, and explore new opportunities and challenges shaping the future of the medical device industry. We invite industry professionals from around the world to register and attend this exhibition—come witness the rapid rise of China's CT core component industry and see firsthand how the "heart" of China's high-end medical equipment is beating stronger than ever, showcasing Chinese innovation and strength on the global medical device stage!

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

Korea Herald

time28-07-2025

  • Korea Herald

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

Korea Herald

time28-07-2025

  • Korea Herald

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

DAEJEON, South Korea, July 28, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI ® (code name: ALT-L9), a biosimilar referencing Eylea ® (aflibercept), co-developed with its subsidiary Alteogen Biologics Inc. EYLUXVI ® has been recommended for approval in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch [RVO] or central [RVO]), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV). "We are pleased to receive a positive CHMP recommendation for EYLUXVI ®. This marks a significant milestone for Alteogen," said Soon-Jae Park, PhD, Chief Executive Officer of Alteogen. "We will provide a new, accessible treatment option for patients suffering from devastating ocular diseases such as wet age-related macular degeneration," he added. The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI ® and reference aflibercept in patients with wet AMD. Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin ® biosimilar, ALT-L2, for the Chinese market to Qilu Pharmaceutical in 2017. Qilu Pharmaceutical completed its development, obtained approval from Chinese regulatory authorities last year, and is currently marketing the product in China. If approved, EYLUXVI ® will be Alteogen's second commercialized biosimilar product. About the ALT-L9 Phase 3 study The study is a randomized, double-masked, parallel group phase 3 study conducted at 79 centers in 12 countries from June 2022 to February 2024, including follow-up through 52 weeks. 431 participants with wet AMD were randomized 1:1 to receive either ALT-L9 (n = 216) or Eylea® (n = 215). The primary efficacy endpoint of the study was the change from baseline in best corrected visual acuity (BCVA). About Alteogen Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ ( For more information, please visit: Contacts:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store